N
SLS icon

Nuveen’s SELLAS Life Sciences SLS Stock Holding History

Nuveen’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.84M Sell
670,974
-352,987
-34% -$1.58M ﹤0.01% 2136
2025
Q4 		$3.86M Buy
1,023,961
+26,051
+3% +$50.6K ﹤0.01% 2019
2025
Q3 		$1.61M Buy
997,910
+26,581
+3% +$47.3K ﹤0.01% 2392
2025
Q2 		$2.13M Buy
+971,329
New +$1.49M ﹤0.01% 2277

Other funds holding SLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Nuveen's SLS Position: Q1 2026 in Review

Nuveen reduced its SELLAS Life Sciences (SLS) stake by 34% in Q1 2026, selling an estimated $1.58M and leaving 670,974 shares worth $2.84M. The position accounts for ﹤0.01% of the portfolio, ranked #2136.

Nuveen first reported a position in SLS in Q2 2025 and has held it in 4 quarters since. The position peaked at $3.86M in Q4 2025. 160 funds tracked by Wall St. Rank hold SLS as of Q1 2026.

  • Nuveen held 670,974 shares of SELLAS Life Sciences worth $2.84M as of Q1 2026.
  • Nuveen sold 352,987 SELLAS Life Sciences shares in Q1 2026, an estimated $1.58M.
  • SELLAS Life Sciences made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #2136 holding.
  • Nuveen first reported a position in SELLAS Life Sciences in Q2 2025 and has held it in 4 quarters since.
  • Nuveen's SELLAS Life Sciences position peaked at $3.86M in Q4 2025.
  • 160 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.